Although little data is currently available, we can hypothesize that sPD-L1 is actively shed by tumor cells as it was found that patients with decreasing sPD-L1 levels after nivolumab initiation presented with better outcomes [25]. The gene discussed is SPDL1; the disease is neoplasm.